BR0312175A - Composto, composição farmacêutica, uso de um composto, método para o tratamento e método para reduzir a morbidez e a mortalidade associadas com o excesso de peso - Google Patents
Composto, composição farmacêutica, uso de um composto, método para o tratamento e método para reduzir a morbidez e a mortalidade associadas com o excesso de pesoInfo
- Publication number
- BR0312175A BR0312175A BR0312175-5A BR0312175A BR0312175A BR 0312175 A BR0312175 A BR 0312175A BR 0312175 A BR0312175 A BR 0312175A BR 0312175 A BR0312175 A BR 0312175A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutically acceptable
- overweight
- treatment
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, MéTODO PARA O TRATAMENTO E MéTODO PARA REDUZIR A MORBIDEZ E A MORTALIDADE ASSOCIADAS COM O EXCESSO DE PESO". A presente invenção refere-se a novos indolos tetracíclicos de arilalquila, seus derivados, seus análogos, suas formas tautoméricas, seus estéreo isomêros, seus polimorfos, seus sais farmaceuticamente aceitáveis, seus solvatos farmaceutica mente aceitáveis, aos novos intermediários aqui descritos e às composições farmaceuticamente aceitáveis contendo os mesmos. A presente invenção refere-se particularmente a novos indolos tetracíclicos de arilalquila tendo a fórmula geral (I), seus derivados, seus análogos, suas formas tautoméricas, seus estéreo isomêros, seus polimorfos, seus sais farmaceuticamente aceitáveis, seus solvatos farmaceuticamente aceitáveis, aos novos intermediários aqui descritos e às composições farmaceuticamente aceitáveis contendo os mesmos. A presente invenção também referese ao(s) processo(s) para a preparação de tal(is ) composto(s) tendo a fórmula geral (I), às composições contendo quantidade(s) efetiva de tal composto e ao uso de tal composto/composição em terapias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN476CH2002 | 2002-06-21 | ||
| PCT/IN2003/000224 WO2004000845A1 (en) | 2002-06-21 | 2003-06-19 | Arylalkyl indoles having sertonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0312175A true BR0312175A (pt) | 2005-04-05 |
Family
ID=29798511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0312175-5A BR0312175A (pt) | 2002-06-21 | 2003-06-19 | Composto, composição farmacêutica, uso de um composto, método para o tratamento e método para reduzir a morbidez e a mortalidade associadas com o excesso de peso |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7297711B2 (pt) |
| EP (1) | EP1537113B9 (pt) |
| JP (1) | JP4455992B2 (pt) |
| CN (1) | CN1662538A (pt) |
| AT (1) | ATE444965T1 (pt) |
| AU (1) | AU2003249584B9 (pt) |
| BR (1) | BR0312175A (pt) |
| CA (1) | CA2490115C (pt) |
| DE (1) | DE60329607D1 (pt) |
| DK (1) | DK1537113T5 (pt) |
| ES (1) | ES2336664T3 (pt) |
| HK (1) | HK1074842A1 (pt) |
| MX (1) | MXPA04012834A (pt) |
| NZ (1) | NZ537772A (pt) |
| RU (1) | RU2320663C2 (pt) |
| WO (1) | WO2004000845A1 (pt) |
| ZA (1) | ZA200409888B (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003292510B2 (en) * | 2002-12-18 | 2009-04-23 | Suven Life Sciences Limited | Tetracyclic 3-substituted indoles having serotonin receptor affinity |
| WO2005066184A1 (en) * | 2004-01-02 | 2005-07-21 | Suven Life Sciences Limited | Novel indeno[2,1a]indenes and isoindol[2,1-a]indoles |
| EP1937255A4 (en) * | 2005-09-14 | 2013-06-26 | Univ Witwatersrand Jhb | PHARMACEUTICAL COMPOSITION |
| JP4950490B2 (ja) * | 2005-12-28 | 2012-06-13 | 株式会社東芝 | 不揮発性スイッチング素子およびその製造方法ならびに不揮発性スイッチング素子を有する集積回路 |
| MX2011001062A (es) * | 2008-07-30 | 2011-03-24 | Ferrer Int | Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno. |
| CN110590748A (zh) * | 2019-10-03 | 2019-12-20 | 黄泳华 | 芳香基氨基苄基哌嗪氮氧化物及其组合物与用途 |
| JP2023508469A (ja) | 2019-12-26 | 2023-03-02 | ギルガメッシュ・ファーマシューティカルズ・インコーポレイテッド | アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 |
| CN115135320B (zh) | 2020-02-18 | 2023-08-29 | 吉尔伽美什制药公司 | 用于治疗情绪障碍的特定色胺 |
| MX2022014605A (es) | 2020-05-19 | 2022-12-16 | Cybin Irl Ltd | Derivados de triptamina deuterada y metodos de uso. |
| JP2023539949A (ja) | 2020-09-01 | 2023-09-20 | エンベリック バイオサイエンシズ カナダ インコーポレイテッド | ハロゲン化シロシビン誘導体および使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA795239B (en) | 1978-10-12 | 1980-11-26 | Glaxo Group Ltd | Heterocyclic compounds |
| ZA815541B (en) * | 1980-08-12 | 1983-03-30 | Glaxo Group Ltd | Heterocyclic compounds |
| GB8600397D0 (en) * | 1986-01-08 | 1986-02-12 | Glaxo Group Ltd | Chemical compounds |
| GB8719167D0 (en) | 1987-08-13 | 1987-09-23 | Glaxo Group Ltd | Chemical compounds |
| GB8724912D0 (en) | 1987-10-23 | 1987-11-25 | Wellcome Found | Indole derivatives |
| GB8819024D0 (en) | 1988-08-10 | 1988-09-14 | Glaxo Group Ltd | Chemical compounds |
| IL96891A0 (en) | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
| CA2042295A1 (fr) | 1990-05-15 | 1991-11-16 | Jacques Chauveau | Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant |
| SI21560B (sl) | 1990-06-07 | 2005-04-30 | Astrazeneca Ab | 3,5-disubstituirani indolni derivati kot "5-HT1-podobni" receptorski agonisti |
| CZ283018B6 (cs) | 1991-02-01 | 1997-12-17 | Merck Sharp And Dohme Limited | Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi |
| GB9113802D0 (en) | 1991-06-26 | 1991-08-14 | Smithkline Beecham Plc | Medicaments |
| US5206382A (en) * | 1991-06-27 | 1993-04-27 | Fidia Georgetown Institute For The Neurosciences | Indole derivatives, pharmaceutical compositions and methods of treating neurological and psychiatric disorders |
| GB9210400D0 (en) | 1992-05-15 | 1992-07-01 | Merck Sharp & Dohme | Therapeutic agents |
| KR940007001A (ko) | 1992-09-16 | 1994-04-26 | 최승주 | 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제 |
| FR2821843B1 (fr) * | 2001-03-12 | 2003-05-09 | Servier Lab | Nouveaux derives d'isoindoloindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2003
- 2003-06-19 AT AT03760859T patent/ATE444965T1/de active
- 2003-06-19 US US10/518,624 patent/US7297711B2/en not_active Expired - Lifetime
- 2003-06-19 CN CN038145979A patent/CN1662538A/zh active Pending
- 2003-06-19 MX MXPA04012834A patent/MXPA04012834A/es active IP Right Grant
- 2003-06-19 ES ES03760859T patent/ES2336664T3/es not_active Expired - Lifetime
- 2003-06-19 JP JP2004515420A patent/JP4455992B2/ja not_active Expired - Fee Related
- 2003-06-19 WO PCT/IN2003/000224 patent/WO2004000845A1/en active Application Filing
- 2003-06-19 EP EP03760859A patent/EP1537113B9/en not_active Expired - Lifetime
- 2003-06-19 DE DE60329607T patent/DE60329607D1/de not_active Expired - Lifetime
- 2003-06-19 BR BR0312175-5A patent/BR0312175A/pt not_active IP Right Cessation
- 2003-06-19 AU AU2003249584A patent/AU2003249584B9/en not_active Ceased
- 2003-06-19 DK DK03760859.3T patent/DK1537113T5/da active
- 2003-06-19 CA CA002490115A patent/CA2490115C/en not_active Expired - Fee Related
- 2003-06-19 NZ NZ537772A patent/NZ537772A/en not_active IP Right Cessation
- 2003-06-19 RU RU2005101343/04A patent/RU2320663C2/ru not_active IP Right Cessation
-
2004
- 2004-12-07 ZA ZA200409888A patent/ZA200409888B/en unknown
-
2005
- 2005-10-06 HK HK05108863.2A patent/HK1074842A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60329607D1 (de) | 2009-11-19 |
| CA2490115C (en) | 2009-09-01 |
| EP1537113B1 (en) | 2009-10-07 |
| RU2005101343A (ru) | 2005-11-20 |
| ZA200409888B (en) | 2006-07-26 |
| DK1537113T3 (da) | 2010-02-15 |
| US7297711B2 (en) | 2007-11-20 |
| RU2320663C2 (ru) | 2008-03-27 |
| HK1074842A1 (en) | 2005-11-25 |
| DK1537113T5 (da) | 2011-01-10 |
| CN1662538A (zh) | 2005-08-31 |
| EP1537113B9 (en) | 2010-05-26 |
| EP1537113A1 (en) | 2005-06-08 |
| MXPA04012834A (es) | 2005-04-25 |
| ATE444965T1 (de) | 2009-10-15 |
| CA2490115A1 (en) | 2003-12-31 |
| AU2003249584B9 (en) | 2008-05-15 |
| WO2004000845A1 (en) | 2003-12-31 |
| NZ537772A (en) | 2007-05-31 |
| JP4455992B2 (ja) | 2010-04-21 |
| AU2003249584B2 (en) | 2007-10-25 |
| US20050203103A1 (en) | 2005-09-15 |
| JP2006501175A (ja) | 2006-01-12 |
| AU2003249584A1 (en) | 2004-01-06 |
| ES2336664T3 (es) | 2010-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0315959A (pt) | Composto, composição farmacêutica uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto | |
| CY1111876T1 (el) | Νεες πυρρολες με υπολiπiδaiμiκες και υποχοληστερολαιμικες δραστικοτητες, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που τις περιεχουν και η χρηση αυτων στην ιατρικη | |
| HK1074842A1 (en) | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | |
| HK1074843A1 (en) | Tetracyclic arylsulfonyl indoles having serotonin receptor affinity | |
| EA200200770A1 (ru) | Производные пурина | |
| MY141559A (en) | Triazole derivatives as tachykinin receptor antagonists | |
| BR0317435A (pt) | Derivados de pirimidina para o tratamento do crescimento celular anormal | |
| EA200200360A1 (ru) | Производные пурина | |
| MX2007008614A (es) | Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r). | |
| EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| EA200400762A1 (ru) | Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции | |
| NO20050666L (no) | 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer | |
| WO2003084937A3 (en) | Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases | |
| NO20061981L (no) | Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist | |
| BR0308145A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| YU54902A (sh) | Nova jedinjenja koja ispoljavaju hipolipidemijsku i hipoholesterolemijsku aktivnost, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže | |
| BR0308144A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| DE602004005960D1 (de) | Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten | |
| YU75101A (sh) | Supstituisani biciklični heterocikli, postupak njihove izrade i njihova upotreba kao antigojaznih i hipoholesterolemijskih agenasa | |
| HK1074630A1 (en) | Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | |
| PE20030725A1 (es) | Compuestos hexaciclicos | |
| RS20050426A (en) | Substituted aralkyl derivatives | |
| BR112023025793A2 (pt) | Composto de fórmula (ii), um estereoisômero deste ou um sal farmaceuticamente aceitável deste, composição farmacêutica e uso do composto | |
| CY1109966T1 (el) | Υποκατεστημενα αραλκυλοπαραγωγα |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/11/2017, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2624 DE 20-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |